🇯🇵·8h agoIndustry
Filing of Humanized Anti-CD20 Monoclonal Antibody Gazyva for Additional Indication of Idiopathic Nephrotic Syndrome
Publisher
C
Chugai Pharmaceutical
Japan
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on chugai-pharm.co.jp
Leave the platform to read the original full article on the publisher site.
Source: Chugai Pharmaceutical
Scope: Industry
Related coverage
More related coverage
Eli Lilly News·4h ago
Lilly and UNICEF collaborate to give millions of children a healthier start
Chugai Pharmaceutical News·8h ago
ヒト化抗CD20モノクローナル抗体「ガザイバ」特発性ネフローゼ症候群に対して適応拡大申請
Astellas Pharma·9h ago
Astellas Submits Supplemental New Drug Application in Japan for PADCEV™ (enfortumab vedotin) plus Keytruda® (pembrolizumab) in Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer
Ipsen RSS·9h ago